Abstract B044: Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survival
Aaron B. Beasley, Elin S. Gray(Edith Cowan University), Wei Yen Chan(The University of Sydney), Peter K. H. Lau(Sir Charles Gairdner Hospital), Leslie Calapre(Edith Cowan University), Helen Rizos(Macquarie University), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(Westmead Hospital), Tarek Meniawy(St John of God Subiaco Hospital), Michael Millward(The University of Western Australia), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(University of California, San Francisco), Lydia Warburton(Edith Cowan University), Jenny Lee(Blacktown & Mount Druitt Hospital), Muhammad A. Khattak, Rebecca Auzins(Edith Cowan University), Alexander M. Menzies(The University of Sydney), Luisa Pinnel(Edith Cowan University), Anna Reid(Edith Cowan University)
Cited by 0
Related Papers
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656